Publication | Closed Access

Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial

MedicinePathologyBronchial NeoplasmCancer TreatmentCancer GeneticsPhase 2OncologyRadiation OncologyLung CancerMolecular OncologyInsertion Mutation